Takeda Pharmaceutical Co. Ltd. · TSE:4502
Takeda Pharmaceutical — 32nd Annual J.P. Morgan Healthcare Conference (January 2014)
23 slides from Takeda Pharmaceutical's conference presentation, Jan 13, 2014
Slide 1: Takeda Pharmaceutical Company - 32nd Annual J.P. Morgan Healthcare Conference
Takeda Pharmaceutical Company 32nd Annual J.P. Morgan Healthcare Conference January 13, 2014 Yasuchika Hasegawa President & CEO
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements regarding the Company's plans, outlook, strategies, and results for the future. All forward-looking statements are based on judgments derived from the information available to the Company at this time. Forward looking s
Slide 3: Takeda Today
Takeda Today Global presence Diverse product portfolio Low patent expiry exposure Success in transformative and value-creating acquisitions and partnerships High potential late-stage pipeline Strong balance sheet, low net debt Significant profit improvement expected from sales growth and our efficie
Slide 4: Sustainable Growth Guidance
Sustainable Growth Guidance Sales growth in Growth Emerging Markets Mid single digit Mature Markets Sales FY13-17 CAGR + Pipeline Efficiency Robust and Operating At least 20% efficient operating Income FY13-17 model CAGR Shareholder Attractive Return shareholder Dividend remuneration per share FY13-
Slide 5: Marketing Strategy - Globalization
Marketing Strategy - Globalization 5
Slide 6: Well Diversified Geographic Footprint
Well Diversified Geographic Footprint Sales in billion yen FY17 Outlook: >2,000 FY13 Outlook: 1,680 27% 19% 33% 43% 14% 15% 24% 25% Japan North America Europe Emerging Markets Mature Markets growth from new innovative products Emerging Markets growth from strong base in BGx & OTC, accelerated by inc
Slide 7: Japan Strategy – Maintain No. 1 Share
Japan Strategy – Maintain No. 1 Share Positive Takeda's Strategy FY13-17 Sales Adapt to Rapidly Changing Home Market Growth Challenges Opportunities Regular price cuts Price benefits for innovation Increase of generic use Increase of lifestyle-related diseases Aging population New Product Sales Inno
Slide 8: US Strategy – Expand Portfolio
US Strategy – Expand Portfolio FY13-17 Takeda's Strategy sales CAGR Steady Growth from Existing Portfolio ≥ 12% VELCADE, COLCRYS, DEXILANT, ULORIC, NESINA family, etc. Optimization of Resources to Support New Launches FY13 FY14 New Launches CONTRAVE® Obesity ENTYVIOTM Crohn's Disease ENTYVIOTM BRINT
Slide 9: EU Strategy – Focus on Specialty Care
EU Strategy – Focus on Specialty Care FY13-17 Takeda's Strategy sales CAGR Strengthen Foundations in Accelerate Presence in ≥ 4% Primary Care Specialty Care VIPIDIA family, dexlansoprazole, etc. ENTYVIO, ADCETRIS, LATUDA, etc. Europe Sales Breakdown FY17 outlook FY13 outlook 15% 10% 45% ADCETRIS® (b
Slide 10: Emerging Markets Strategy – Maintain Strong Momentum
Emerging Markets Strategy – Maintain Strong Momentum FY13-17 Takeda's Strategy sales CAGR Capitalize upon Global Sales Channel ≥ 15% Accelerate Growth Through Further Investment Like-for-like* (billion yen) 61.3 +28.3% 16.9 +17.2% 47.8 Russia/CIS 14.4 18.7 +20.0% Latin America 15.6 Asia 15.7 +20.5%
Slide 11: Emerging Markets Strategy – China, Russia/CIS and Brazil
Emerging Markets Strategy – China, Russia/CIS and Brazil China • Maximize sales of existing products FY13-17 (Ulinastatin, pantoprazole, leuprorelin, etc.) sales • Increase presence in diabetes (NESINA co-promotion) CAGR* • Improve profitability ≥ 25% Russia/CIS • Maximize ROI from balanced portfoli
Slide 12: R&D Strategy - Innovation
| R&D Strategy - innovation = 12 Takeda Pharmaceutical Company Limited
Slide 13: Increasing R&D Productivity
Increasing R&D Productivity Quality of Thought Enrich Maximize/deliver Invigorate the Mid-stage the Late-stage Discovery Pipeline Pipeline Operational Excellence • Fast to candidate • Mono-oki project • Life-cycle management • Fast to IND • Fast to POC • Prioritize high potential • Global target mar
Slide 14: Enhancing Late-Stage Pipeline in Core Therapeutic Areas
Enhancing Late-Stage Pipeline in Core Therapeutic Areas 6 CV/Metabolic Immunology/Respiratory Oncology General Medicine CNS Vaccine therapeutic areas 21 11 12 phase 3 projects* filed projects* approved projects in FY2013 to date* *Includes life-cycle management and fixed-dose combinations Each proje
Slide 15: High Potential Pipeline Assets
High Potential Pipeline Assets ENTYVIO (vedolizumab) MLN9708 (ixazomib citrate) • Gut-selective monoclonal antibody targets α4β7 • Once weekly oral proteasome inhibitor integrin on leukocytes involved in ulcerative colitis • On-going clinical trials include Phase 3 in front line (UC) and Crohn’s dis
Slide 16: Increasing Presence in Vaccines
Increasing Presence in Vaccines Norovirus Vaccine p=0.042 20 • Acquired with LigoCyte in October 2012 No. of Challenged • Potential to be first-in-class vaccine Subjects with Mild, No. of Challenged 15 Moderate or Severe against norovirus Subjects with Mild, Vaccine Acute Gastroenteritis Moderate or
Slide 17: Ensuring Steady Pipeline Approval
Ensuring Steady Pipeline Approval FY13 FY14 FY15 FY16-FY17 FY13 FY14 FY15 FY16-17 OBLEAN SYR-472 ADCETRIS MLN9708 Lu AA21004 TAK-385 TAKEPRON/LDA TAK-700* JP TAK-438 motesanib BLB-750 LEUPLIN/6M TAK-816 AZILVA/CCB TAK-700* MLN9708 BRINTELLIX TAK-375SL US ENTYVIO MLN8237 VIPIDIA family MLN9708 EU LAT
Slide 18: Financial Strategy
18 Takeda Pharmaceutical Company Limited
Slide 19: Project Summit: Raising Competitiveness
Project Summit: Raising Competitiveness Implement global operating models and establish best-in-class business processes, boosting profitability and capacity for investments in growth Sales & Marketing Research & Development FY15 FY17 Yearly Savings Targets: >80 >100 billion yen billion yen Low sing
Slide 20: Cash Generation and Cash Use
Cash Generation and Cash Use • Increase sales of new products Cash • Increase sales in emerging markets Generation • Streamline balance sheet • Maintain ¥180 dividend for FY13-15 Cash Use • Steadily repay debt • Continue investment for sustainable growth All Debts Paid Back by 2020 Double FCF* from
Slide 21: Sustainable Growth Guidance
Sustainable Growth Guidance Sales growth in Growth Emerging Markets Mid single digit Mature Markets Sales FY13-17 CAGR + Pipeline Efficiency Robust and Operating At least 20% efficient operating Income FY13-17 model CAGR Shareholder Attractive Return shareholder Dividend remuneration per share FY13-
Slide 22: Takeda's Bright Future
Takeda's Bright Future • Our marketing strategy is tailored to each region • Our late-stage pipeline is both rich and deep; the impact of patent expiries is limited in the short- to mid- term • We will continue to take bold and transformative steps to make every area of our company more effective, e
Slide 23: End of Presentation
| End of Presentation — 23 Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company — 32nd Annual J.P. Morgan Healthcare Conference (January 2014) on 6ix